Coya Therapeutics (COYA) Expected to Announce Earnings on Wednesday

Coya Therapeutics (NASDAQ:COYA) is expected to issue its Q3 2025 results before the market opens on Wednesday, November 5th. Analysts expect the company to announce earnings of $0.02 per share and revenue of $3.6970 million for the quarter. Individuals may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Wednesday, November 5, 2025 at 8:00 AM ET.

Coya Therapeutics (NASDAQ:COYA) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.14). The business had revenue of $0.16 million during the quarter, compared to analysts’ expectations of $0.78 million. On average, analysts expect Coya Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Coya Therapeutics Stock Performance

Shares of COYA stock opened at $6.66 on Wednesday. Coya Therapeutics has a 1 year low of $4.65 and a 1 year high of $9.64. The business’s fifty day moving average is $6.23 and its 200-day moving average is $6.03. The stock has a market cap of $111.49 million, a PE ratio of -5.37 and a beta of 0.19.

Hedge Funds Weigh In On Coya Therapeutics

A hedge fund recently bought a new stake in Coya Therapeutics stock. Northwestern Mutual Wealth Management Co. acquired a new position in shares of Coya Therapeutics, Inc. (NASDAQ:COYA) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 20,626 shares of the company’s stock, valued at approximately $119,000. Northwestern Mutual Wealth Management Co. owned approximately 0.12% of Coya Therapeutics as of its most recent filing with the Securities and Exchange Commission. 39.75% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research firms recently issued reports on COYA. HC Wainwright reaffirmed a “buy” rating and set a $18.00 target price on shares of Coya Therapeutics in a report on Monday, August 25th. Chardan Capital reaffirmed a “buy” rating and issued a $14.00 price objective on shares of Coya Therapeutics in a research note on Wednesday, September 17th. D. Boral Capital reiterated a “buy” rating and issued a $18.00 target price on shares of Coya Therapeutics in a report on Monday, September 29th. Lake Street Capital assumed coverage on shares of Coya Therapeutics in a report on Wednesday, July 9th. They set a “buy” rating and a $16.00 target price for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Coya Therapeutics in a report on Wednesday, October 8th. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Coya Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $16.20.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.